AU Patent

AU2005285045B2 — Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Assigned to Gilead Sciences Inc · Expires 2011-10-13 · 15y expired

What this patent protects

The present invention provides (i) processes for preparing a 2'-deoxy-2'­fluoro-2'-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides…

USPTO Abstract

The present invention provides (i) processes for preparing a 2'-deoxy-2'­fluoro-2'-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2'-deoxy-2'-fluoro-2'-C-­methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally­-occurring, nucleoside.

Drugs covered by this patent

Patent Metadata

Patent number
AU2005285045B2
Jurisdiction
AU
Classification
—
Expires
2011-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.